Big physics, small doses: the use of AMS and PET in human microdosing of development drugs

被引：193

作者：

Lappin, G ^{[1
]}

Garner, RC ^{[1
]}

机构：

[1] Xceleron Ltd, York Bioctr, Res & Dev, York YO10 5NY, N Yorkshire, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2003年 / 2卷 / 03期

关键词：

D O I：

10.1038/nrd1037

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The process of early clinical drug development has changed little over the past 20 years despite an up to 40% failure rate associated with inappropriate drug metabolism and pharmacokinetics of candidate molecules. A new method of obtaining human metabolism data known as microdosing has been developed which will permit smarter candidate selection by taking investigational drugs into humans earlier. Microdosing depends on the availability of two ultrasensitive 'big-physics' techniques: positron emission tomography (PET) can provide pharmacodynamic information, whereas accelerator mass spectrometry (AMS) provides pharmacokinetic information. Microdosing allows safer human studies as well as reducing the use of animals in preclinical toxicology.

引用

页码：233 / 240

页数：8

共 28 条

[1] In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography [J].

Aboagye, EO ;

Price, PM ;

Jones, T .

DRUG DISCOVERY TODAY, 2001, 6 (06) :293-302

[2] The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions [J].

Bachmann, KA ;

Ghosh, R .

CURRENT DRUG METABOLISM, 2001, 2 (03) :299-314

[3] Integration of virtual and high-throughput screening [J].

Bajorath, F .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (11) :882-894

[4] High-throughput crystallography for lead discovery in drug design [J].

Blundell, TL ;

Jhoti, H ;

Abell, C .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) :45-54

[5] Trends in development cycles [J].

Bolten, BM ;

DeGregorio, T .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (05) :335-336

[6] Fundamentals of positron emission tomography and applications in preclinical drug development [J].

Cherry, SR .

JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (05) :482-491

[7] A METHOD OF STUDYING PHARMACOKINETICS IN MAN AT PICOMOLAR DRUG CONCENTRATIONS [J].

CUNNINGHAM, VJ ;

PIKE, VW ;

BAILEY, D ;

FREEMANTLE, CAJ ;

PAGE, BC ;

JONES, AKP ;

KENSETT, MJ ;

BATEMAN, D ;

LUTHRA, SK ;

JONES, T .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (02) :167-172

[8] Risks in new drug development: Approval success rates for investigational drugs [J].

DiMasi, JA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (05) :297-307

[9]

*EUR AG EV MED, 2002, POS PAP NONCL SAF ST

[10] Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor [J].

Garner, RC ;

Goris, I ;

Laenen, AAE ;

Vanhoutte, E ;

Meuldermans, W ;

Gregory, S ;

Garner, JV ;

Leong, D ;

Whattam, M ;

Calam, A ;

Snel, CAW .

DRUG METABOLISM AND DISPOSITION, 2002, 30 (07) :823-830

← 1 2 3 →